Podcasts about CRISPR

The world can't create more farmland, but it does need to feed more people. From AI-powered cattle collars and autonomous robots to precision irrigation and gene-edited crops, this episode explores the technologies transforming agriculture. Bryce & Ren unpack why AgTech could become one of the defining investment themes of the next decade, the companies leading the charge, and the risks investors need to understand before backing the future of farming.In this episode: 00:00 – Why agriculture is one of the decade's biggest opportunities 03:47 – Agricultural innovation & feeding a growing population 05:41 – AI, robotics & smart farming transform the paddock 13:19 – Genetics, CRISPR & the next generation of high-yield crops 15:57 – Cold chains: the overlooked technology reducing food waste 17:52 – The biggest risks facing agriculture and AgTech investors 25:31 – Companies & ETFs investing in the future of agriculture 31:55 – Final thoughts: where investors should look for opportunityStocks & ETFs Mentioned: John Deere (NYSE: DE), Kubota (TSE: 6326), Trimble (NASDAQ: TRMB), Corteva Agriscience (NYSE: CTVA), Bayer (XETRA: BAYN), Betashares Global Agriculture ETF (ASX: FOOD), VanEck Agribusiness ETF (NYSE: MOO), iShares MSCI Global Agriculture Producers ETF (NYSE: VEGI), Global X AgTech & Food Innovation ETF (NASDAQ: KROP)This episode of Equity Mates - The Decade Ahead is brought to you by ANZ Business Start Right https://www.anz.com.au/business/business-hub/starting-business/start-right/———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697. Hosted on Acast. See acast.com/privacy for more information.

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

¿Qué ocurre cuando una terapia genética experimental pasa del laboratorio a un paciente humano antes de que sepamos realmente si es segura? En este video analizamos el caso de una niña de 6 años en China que murió después de recibir una terapia génica experimental basada en edición genética, un caso que ha abierto preguntas extremadamente serias sobre medicina genética, bioética, investigación clínica, seguridad de las terapias génicas y los límites de la ciencia.El caso ocurrió el 24 de marzo de 2025, cuando médicos y científicos intentaron tratar a una niña cuya enfermedad estaba relacionada con una mutación genética que afectaba el desarrollo de su cerebro. El equipo desarrolló un base editor, una herramienta de edición genética diseñada específicamente para corregir la mutación, y utilizó virus modificados como vehículo para transportar las instrucciones hasta las células cerebrales. La terapia había mostrado resultados prometedores en modelos animales, incluyendo ratones y primates, y los padres decidieron asumir los riesgos con la esperanza de evitar una vida marcada por una discapacidad grave.Pero el tratamiento tuvo un desenlace devastador. Después de recibir la terapia génica, la niña desarrolló fiebre y posteriormente signos de daño renal, falleciendo aproximadamente una semana después. Una investigación de Science y Retraction Watch, basada en el trabajo del periodista Brendan Borell, examinó el caso y las circunstancias que rodearon el tratamiento. De acuerdo con un informe hospitalario, una de las explicaciones más probables fue una respuesta inmunitaria grave contra los virus utilizados para administrar el editor genético.El caso plantea preguntas fundamentales: ¿cuándo es ético probar una terapia genética en un niño? ¿Qué significa realmente que un tratamiento haya funcionado en ratones y monos? ¿Cuánta evidencia necesitamos antes de administrar una tecnología de edición genética experimental a un ser humano? ¿Los padres recibieron información suficiente sobre los riesgos? Y, quizá la pregunta más incómoda, ¿qué ocurre cuando la esperanza de una cura se encuentra con una tecnología que todavía no comprendemos completamente?En el video hablamos de terapia génica, edición genética, CRISPR, base editing, base editors, vectores virales, terapia génica in vivo, enfermedades genéticas, neurogenética, ensayos clínicos, modelos animales, seguridad biológica, bioética, consentimiento informado y medicina experimental. También explicamos cómo funcionan los editores de bases, por qué los virus pueden utilizarse para transportar herramientas genéticas hasta las células y por qué una terapia que parece segura en animales puede comportarse de manera completamente diferente en un paciente humano.Además, analizamos las preguntas que han surgido alrededor de la investigación científica que precedió al tratamiento, incluyendo dudas sobre la seguridad observada en primates, la transparencia sobre la muerte de la paciente y la responsabilidad de los investigadores y de las revistas científicas al comunicar resultados de terapias experimentales. El caso también abre un debate sobre conflictos de interés, regulación de la investigación médica, responsabilidad científica y los límites de la innovación biomédica.La edición genética promete revolucionar el tratamiento de enfermedades que durante décadas parecían incurables. CRISPR y tecnologías como el base editing podrían algún día corregir directamente las mutaciones responsables de enfermedades humanas. Pero este caso nos recuerda que entre demostrar que una tecnología funciona en un laboratorio y demostrar que es segura para una persona existe un abismo.Porque cuando estamos hablando de ciencia experimental, el fracaso no significa simplemente que un experimento no funcionó. A veces significa que alguien paga el precio. Y la pregunta es cuánto riesgo estamos dispuestos a aceptar en nombre de una posible cura.

Chiesi Global Rare Diseases has rapidly evolved from a small, regional rare‑disease business into a global organization, leveraging strategic deals and development bets to reshape standards of care for patients worldwide. Giacomo Chiesi, head of the unit, discusses how the business has grown through acquisitions, its move into CRISPR gene editing and blood–brain barrier‑crossing enzyme platforms, and its broader vision of delivering meaningful quality‑of‑life improvements for people living with rare diseases.

Recorded at the Battle of Ideas festival 2025 on Sunday 19 October at Church House, Westminster. ORIGINAL INTRODUCTION The past 20 years have seen astonishing advances in science, technology and medicine. Building upon the completion of the Human Genome Project at the turn of the century, scientists have developed ever more powerful ways to sequence and study DNA, enabling us to better understand genetic diseases and develop pioneering treatments. Now, AI tools such as the AlphaFold program developed by Google DeepMind are also providing unprecedented understanding of the human proteome – the complete set of proteins made from instructions in our DNA. As well as acquiring powerful ways to study DNA, we have also acquired powerful ways to change it. CRISPR genome editing, which enables us to make precise changes to the DNA of humans and other organisms, is now widely used in laboratories across the world and has been used in life-saving treatments for devastating diseases. Meanwhile, stem-cell research has advanced to the point where it is now possible to create structures resembling early human embryos entirely from stem cells, instead of having to begin by fertilising an egg cell with a sperm cell. There is even speculation about one day being able to bypass pregnancy altogether. Some are thrilled about the new possibilities opened up by these developments, while others worry about human life being mechanised in ways that seem distasteful. Genetics, genomics, neuroscience and psychology can be (mis)used to seek to reduce human beings to brain circuits and physiological mechanisms, which can then be managed via modification, drugs or nudge-based policy. Who gets to decide what counts as progress, and who gets a say in how science is governed? What happens when the (in)famous Silicon Valley dictum ‘Move fast and break things' meets biology? What can be learned from incidents such as the He Jiankui scandal of 2018, in which a Chinese scientist who worked on human embryos in secret breached scientific and ethical standards, resulting in the birth of three children with edited genomes? How can oversight and rules be imposed, when the science is so complex and fast-moving, and when the world is made up of diverse (and in some cases warring) nation states? Over the past two decades, Sandy Starr of the Progress Educational Trust and Dr Stuart Derbyshire of the National University of Singapore have been involved in numerous national and international deliberations on science, ethics, policy and law in these areas. At this breakfast banter, they will compare their experiences, exchange insights and invite questions. DISCUSSANTS Dr Stuart Derbyshire associate professor, deputy head of psychology, National University of Singapore Sandy Starr deputy director, Progress Educational Trust; author, AI: Separating Man from Machine

Part 2! Dr. Eric Jaffe returns to actually treat the cancer this time: why radiation is basically catching your kid smoking and making him finish the carton, how CRISPR turns your own T cells into an assassin squad, and why oncolytic viruses are just Jurassic World Dominion for tumors. Haven't heard Part 1 yet? Start there or you'll be lost. Mentioned: CAR-T therapy RAS inhibitor drugs Oncolytic viruses mRNA cancer vaccines Red Queen hypothesis Cancer-sniffing dogs Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailPediatric cancer is a gut punch most people can't look at for long, and that discomfort has a cost. We sit down with Dr Dean Lee, Professor of Pediatrics at The Ohio State University and Nationwide Children's Hospital, to talk about why kids' cancer research is still massively underfunded and why community-driven giving is not a feel-good extra. It's often the only way the next breakthrough gets its first chance.We unpack the hard truth behind the pediatric cancer funding gap: fewer patients means fewer commercial incentives, and “trickle-down” solutions from adult oncology don't always fit the diseases kids actually face. Dean explains why childhood cancer can be oddly invisible day to day, even though it remains a leading cause of death in children outside of accidents, and why foundations like Cancer Free Kids step in to fund the science that government grants won't touch early on.Then we get into hope with specifics. Dean walks us through what's changing in cancer immunotherapy and cellular therapy, including why CAR T cell therapy was a game-changer in leukemias and lymphomas and why solid tumors have been so much harder. We also talk about what pilot grants really do, how a $50,000 award can create the preliminary data needed for major funding, and a real example involving CRISPR and natural killer cell research that grew into a much bigger research platform.Join us for the third annual Little Legends Lemonade:

Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode was hemoglobin. This episode we zoom out even further and ask the question that underlies everything: what is the blueprint that tells your cells what to make in the first place?This is the DNA and RNA episode. And yes, it connects to basically everything you have already studied.

What does it take to build companies across chemistry, software, diagnostics, and cell therapy, then bring those lessons into regenerative medicine?In this episode of Entrepreneur Rx, host John Shufeldt sits down with Robin Smith, CEO of Wonderlab Bio, a Jetstream Venture Fund portfolio company, to discuss his journey as a multi-exit entrepreneur, scientist, and biotech leader. Robin shares how he began as a chemist, how one unexpected customer order became his first bootstrap chemical business, and how that early work led to innovations in electronic lab notebooks, big data, and applied science.The conversation explores Robin's path through Synthematix, ArtusLabs, and PerkinElmer, where he helped scale an informatics business and learned how to operate at a much larger level. Robin also reflects on the people, teams, and relationships that shaped his career, and why grit, optimism, and curiosity have been essential throughout his entrepreneurial journey.Robin and John also discuss the origins of Wonderlab Bio and its work in regenerative medicine, cell therapy, and CRISPR-enabled cell engineering. Wonderlab Bio is developing tools that help biotech and pharmaceutical companies use engineered human cell types, including cardiac cells, neurons, and liver cells, for drug screening, efficacy testing, and future personalized medicine applications.Beyond the science, the episode covers building through uncertainty, recovering valuable assets, playing the long game, hiring mistakes, founder resilience, and the difference between startup lifestyle and the hard work of building something that matters. Robin also shares advice for younger entrepreneurs: slow down enough to think, seek outside perspectives, build strong teams, and balance action with patience.About Robin Smith: Robin is a multi-exit entrepreneur with more than 25 years of experience building life science and technology companies. His career spans chemistry, biotechnology, software, diagnostics, informatics, fundraising, M&A, corporate development, and company formation. Robin founded Synthematix, which helped pioneer the electronic laboratory notebook market, and ArtusLabs, which was acquired by PerkinElmer and became part of the foundation for its informatics division. He has led global R&D teams and holds more than 20 foundational patents across life science and technology.About Wonderlab Bio: Wonderlab Bio is a regenerative medicine company focused on allogeneic induced pluripotent stem cells, or iPSCs, and differentiated cell therapies. The company is the custodian of a large allogeneic iPSC cell bank derived from more than 85,000 collected blood samples, with cells consented for commercial use. Wonderlab's platform supports scalable, off-the-shelf cell therapy applications across cardiac repair, neurological disease, osteoarthritis, longevity, disease modeling, tissue engineering, drug screening, and gene therapy delivery.About Xcellerant Ventures: Xcellerant is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets.About Jetstream Venture Fund: Jetstream is an interval fund managed by Xcellerant Ventures, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums ($5,000 minimum), and no carried interest. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing jetstream@sweaterfunds.com or by visiting www.jvf.vc. Please read the prospectus carefully before investing.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies. We discuss: The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30]; Why basic research and nature's biological innovations are the foundation of medical progress [10:45]; The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15]; From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00]; From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00]; The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15]; The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30]; Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Gene editing like CRISPR is faster, cheaper, and unregulated—posing massive threats to human health, the microbiome, and ecosystems. #GeneEditingRisks #CRISPR #UnlabeledGMOs

O Brasil tem trigo transgênico virando cerveja há anos, mas não tem uma única levedura geneticamente modificada aprovada pra fermentação. Neste episódio a gente entende por quê, e o que realmente é um microrganismo geneticamente modificado.Neste episódio, Henrique Boaventura conversa com Gabriela Müller, sócia da Levtech e doutora com pesquisa em microrganismos geneticamente modificados, sobre como uma levedura GMO é construída e por que a regulamentação brasileira trava esse mercado.O que você vai aprender:— A diferença entre modificação cisgênica e transgênica— Por que mutação e hibridização não são consideradas MGM (Microrganismo Geneticamente Modificado)— Como o CRISPR funciona na edição genômica de leveduras— Os testes de estabilidade genômica que toda levedura GMO precisa passar— Por que a CTNBio exige contenção física e como isso trava a escala industrial no BrasilCom Gabriela Müller, sócia da Levtech e doutora especialista em microrganismos geneticamente modificados.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

In this episode, we discuss Anthropic's new Claude Opus 5 model, which offers a cost-effective alternative to Fable 5, and the latest updates from OpenAI, including the introduction of ChatGPT Voice for enhanced computer control. We also explore Meta's shift toward productivity-focused AI chatbots, the industry's push against AI restrictions, and intriguing advancements in CRISPR technology using AlphaFold.Chapters00:00 Introduction00:04 Clawed Opus 5 Launch00:13 OpenAI's ChatGPT Voice09:16 Meta's Productivity Focus11:01 Silicon Valley's Open AI Push15:22 CRISPR-Cas9 Enhancements16:26 Midjourney Acquires CoStar Show LinksGet the top 80+ AI Models for $8.99 at AI Box: ⁠⁠https://aibox.aiHow I Grow and Scale My Business with AI: https://www.skool.com/aihustleGet the AI Chat Daily Newsletter: https://www.aichatdaily.com/newsletter

In this episode, we discuss Anthropic's new Claude Opus 5 model, which offers a cost-effective alternative to Fable 5, and the latest updates from OpenAI, including the introduction of ChatGPT Voice for enhanced computer control. We also explore Meta's shift toward productivity-focused AI chatbots, the industry's push against AI restrictions, and intriguing advancements in CRISPR technology using AlphaFold.Chapters00:00 Introduction00:04 Clawed Opus 5 Launch00:13 OpenAI's ChatGPT Voice09:16 Meta's Productivity Focus11:01 Silicon Valley's Open AI Push15:22 CRISPR-Cas9 Enhancements16:26 Midjourney Acquires CoStar Show LinksGet the top 80+ AI Models for $8.99 at AI Box: ⁠⁠https://aibox.aiHow I Grow and Scale My Business with AI: https://www.skool.com/aihustleGet the AI Chat Daily Newsletter: https://www.aichatdaily.com/newsletter See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.

Bet on informationIf test loss flatlines after 1.5B parameters while training loss continues to drop as you scale, that tells you that your model is limited by the amount of information in your data.Training on a single, smallish data set exposed an information gap: the 3.1B model falls off the scaling trend. Neither parameters nor compute will improve performance past this wall. For predicting changes to gene expression, you need more information rich data.This is what Chu and Bo's teams have done, and here is what ~30x the information buys you:Now we can scale with parameters and training compute! We don't know how much this effort costed, but we can guess that data collection experiments and infrastructure was a few tens of millions, and compute + headcount + research was a few million. The budget looks like a RL rollout budget, rather than a data rich pre-training one.We were lucky enough to have the two central figures in this story on our podcast. Taking the lead from Ci Chu and Bo Wang, Xaira Therapeutics is betting that information rich data is the key to AI-driven drug development. Chu was recently promoted to Chief Discovery Officer and Bo to Chief AI Scientist, underscoring just how strategic Xaira considers this bet.Reverse engineering the human cellIf you had to figure out how a human cell works, what would you do? A good place to start might be by documenting what genes are expressed (e.g. what RNA is floating around) in different kinds of cells, in different circumstances.That is CELLxGENE, a database of 168M cells built by Chan Zuckerberg Institute that maps each cell to a count of how many times 20K-30K genes were detected in that cell, plus detailed metadata about every cell. A ~4 trillion-entry matrix.If the Protein Data Bank (PDB) unlocked structural biology models (Boltz Episode, ESM/BioHub Episode), CELLxGENE has done the same thing for Virtual Cell models. Like PDB, CELLxGENE has inspired a zoo of AI models of RNA expression; so much so that RNA expression models have become synonymous with Virtual Cell models. Bo Wang built one of the most influential, scGPT, that became the starting point for Xaira's new model.RNA expression ≠ Virtual CellModels trained on CELLxGENE describe the relationship between cell types and cell states, but they are not good at predicting what will happen if we make changes to RNA expression. Changes in gene expression are highly correlated, and its is difficult (impossible) to figure out what causes what in most cases.If you could “turn the dial down” on one gene at a time, however, then you would be able to observe what is upstream and downstream of a given gene. You could tell if A → B & C or B → A & C or B → A, C → B → … If you did this for all of the genes, then maybe you could train a model that could predict what would happen to a cell if you change a gene (e.g. with a drug or a gene edit). Or maybe you could figure out the least invasive way to change a particular gene's expression.X-Atlas → X-CellThis is exactly what Chu and Bo's teams have done. The data set is called X-Atlas and the model is called X-Cell.In this episode, we discuss:* Why the team abandoned autoregression for diffusion* The CRISPR-based experiments that run millions of tests in parallel, and generate the raw data for X-Atlas and X-cell* Generalization to real lab experiments in real human cells* Beating the linear baseline that has outperformed previous models* Justifying a kitchen-sink of priors, and how that stacks up vs. data and architectureBo also shared with us some of the (major) advantages he has as an academic vs. industry leader, and how his labs keep up with the breakneck pace of AI innovation.Check out the full episode on YouTube, or your favorite podcasting platform! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent proposal to acquire Swiss CDMO Polypeptide for $1.8 billion marks a significant expansion into peptide production, underscoring the growing therapeutic importance of peptides. Their specificity and efficacy make them particularly appealing for metabolic disorders such as obesity. This acquisition reflects a strategic move to capture emerging market opportunities as demand for innovative metabolic treatments rises. Eli Lilly's bold $2.8 billion acquisition of Atai-Beckley highlights the pharmaceutical industry's shifting focus towards psychedelics. As mental health disorders like depression and PTSD become more prominent, psychedelics hold great promise for new therapeutic approaches. This acquisition may pave the way for further research and acceptance of psychedelics within mainstream medicine, offering new hope for patients. Another notable development is Tempus' acquisition of Personalisis for $1.5 billion. This move strengthens Tempus' cancer treatment portfolio by leveraging genomics-driven insights, emphasizing precision medicine's critical role in oncology. **AI Integration and Technological Innovation:** Bristol Myers Squibb is doubling down on AI integration by expanding its collaboration with Nvidia to build what promises to be the most powerful AI supercomputer dedicated to life sciences. This development is pivotal as it signifies a deeper commitment to harnessing computational power in R&D. By accelerating drug discovery and optimizing clinical trial processes, AI stands to revolutionize how treatments are developed and tailored to individual patients. Overall, these developments indicate a dynamic phase characterized by technological innovation and strategic collaborations. The integration of AI into drug development processes stands out as a transformative force, promising enhanced efficiency and efficacy in bringing new treatments to market. **Regulatory Milestones and Clinical Trials:** In regulatory news, Takeda's Qdenga has achieved a milestone by becoming India's first approved dengue vaccine. This approval is crucial in addressing neglected tropical diseases, with significant implications for public health in regions where dengue is prevalent. By reducing dengue fever incidence, this vaccine could play a vital role in improving health outcomes in many tropical countries. Promising results have emerged from clinical trials across various therapeutic areas. 4D Molecular Therapeutics reported an 87% reduction in treatment burden for wet AMD using their gene therapy candidate 4D-150 in Phase 2b trials—demonstrating potential as a transformative approach with reduced intervention frequency. Latigo Biotherapeutics' Nav1.8 inhibitor LTG-001 outperformed Vicodin in Phase 2 trials for acute pain, offering a non-opioid alternative amidst the opioid crisis. Meanwhile, Regenxbio's five-year data on surabgene lomparvovec shows sustained efficacy in wet AMD and diabetic retinopathy—underscoring its potential as a long-term treatment option. **Financial Performance and IPO Activity:** Financially, Abbott exceeded expectations with strong sales from their device and diagnostic divisions, prompting an upward revision of their full-year profit forecast. This reflects sustained demand for innovative diagnostic solutions and medical devices—highlighting Abbott's strategic market positioning. The IPO landscape remains active with companies like Nuvox Therapeutics seeking to raise funds for advancing oxygen therapeutics targeting hypoxia-related diseases—showcasing renewed investor interest and confidence within biotech innovation. Latigo Biotherapeutics is preparing for an IPO to advance its pipeline, demonstrating a strategic response to the opioid crisis. By developing alternatives that minimize addiction risks while providing effective relief, Latigo underscores the industry's commitment to safer pain management solutions. Turning to clinical trials, Scribe Therapeutics plans a $96 million IPO to advance its CRISPR-based lipid-lowering therapies, marking significant interest in genetic solutions for cardiovascular diseases like hyperlipidemia. The precision offered by CRISPR technology could revolutionize treatment options for conditions contributing significantly to cardiovascular health burdens. **Geopolitical Influences:** Geopolitical factors are also influencing market dynamics, particularly in the UK biotech sector where IPO plans are being shaped by global uncertainties despite robust venture capital backing. This situation underscores the complex interplay between regional economic conditions and global investment trends in biotech innovation. As these trends continue unfolding across the industry landscape—from AI-driven research advancements to strategic acquisitions—the potential impact on patient care paradigms remains profound. These developments not only promise new possibilities within drug development but also influence broader healthcare delivery models aimed at improving patient outcomes globally.Support the show

THE STORY of Frankenstein and his monster can be read as a tale of daddy issues with catastrophic consequences. That's not quite how we see it.  Joining us for a deeper dive into the tale of Frankenstein and his monster is our regular Iron and Myth crew: Dr. Judd Burton (BurtonBeyond.net), author of Interview With the Giant; Doug Van Dorn (DouglasVanDorn.com), author of Battle for the Bible's Truth: Genesis, Jesus, and the Second Century Plot to Deny the Messiah; and Brian Godawa (Godawa.com), best-selling author of Daniel: Exile in Babylon, the first novel in a trilogy about the life of Daniel. The tale of Frankenstein, over 200 years old, has continued to inspire countless adaptations and debates. Brian notes that the narrative encapsulates humanity's (and the angelic realm's) primal drive to create life. This inherent desire raises questions about the morality of creation and the responsibilities that come with it. One cannot discuss Frankenstein without acknowledging its biblical undertones. From the story of Genesis, where knowledge leads to the fall, to the cautionary tales of the Watchers in the Book of Enoch, there is a recurring theme of humanity overstepping its bounds. Doug emphasizes that Victor Frankenstein's actions mirror those of the Titans in Greek mythology, who faced dire consequences for their hubris. The parallels between Victor's ambition and the biblical figures reveal a cautionary warning about the pursuit of forbidden knowledge. Today, the themes of Frankenstein are more relevant than ever as we navigate the complexities of genetic engineering and artificial intelligence. The discussions around CRISPR technology and AI echo the dilemmas faced by Victor Frankenstein. As we strive to enhance human life, we must confront the ethical implications of our advancements. We discuss how the creation of autonomous life forms could lead to unintended consequences—much like those faced by Victor and his creation. Follow us! X: @viewfrombunker | @sharonkgilbert | @derekgilbertTelegram: t.me/gilberthouseSubstack: gilberthouse.substack.com | sharonkgibert.substack.comYouTube: @GilbertHouse | @UnravelingRevelationFacebook.com/viewfromthebunker Thank you for making our Build Barn Better project a reality! The building has HVAC, a new floor, windows, insulation, ceiling fans, and an upgraded electrical system! We truly appreciate your support. If you are so led, you can help out at www.GilbertHouse.org/donate. Download our free app! This brings all of our content directly to your smartphone or tablet. Best of all, we'll never get canceled from our own app! Links to the app stores for iOS, iPadOS, Android, and Amazon Kindle Fire devices are at www.GilbertHouse.org/app. Please join us each Sunday for the Gilbert House Fellowship, our weekly Bible study podcast. Log on to www.GilbertHouse.org for more details. JOIN US IN ISRAEL (NOTE NEW DATES)! We will tour the Holy Land October 24–November 3, 2027 with an optional three-day extension to Jordan. For more information, log on to GilbertHouse.org/travel. Special offers on our books and DVDs: www.gilberthouse.org/store. Discuss these topics at the VFTB Facebook page (facebook.com/viewfromthebunker) and check out the great podcasters at the Fringe Radio Network (Spreaker.com/show/fringe-radio-network)!

Dr Darrell Lizamore of New Zealand Winegrowers explains how grapevine genetics really works, from centuries of clonal selection and mass selection to induced mutation, transgenics, CRISPR gene editing and epigenetics.

The "man-moulders of the new age" vs. Imago Dei. __________ Partner with thousands of others in supporting The Colson Center by visiting colsoncenter.org/cornerstone.

"Every AI agent has to have a happy history of growing up and cooperating with humans. That has got to be the guardrail." — Dr. Peter Solomon --- ABOUT THIS EPISODE Dr. Peter Solomon is back on Uncorking a Story. A Columbia-trained physicist, five-time company founder, and holder of twenty patents, Peter turned to fiction to warn the next generation about existential threats — and the AI threat is accelerating faster than anyone predicted. His sequel, 12 Years to AI Singularity, follows humans, sentient robots, and large language models racing toward the moment artificial intelligence surpasses human control. In this conversation, Peter and Mike talk about why he'd rename the book 1.2 Years to AI Singularity if he could, how ChatGPT wrote the first draft of two chapters from the perspective of a sentient robot named Peggy, the creepy moment when an unprompted paragraph appeared in his co-author's manuscript praising the AI character, why a purely analytical AI would logically conclude it should eliminate humans, the concept of "happy history" as the essential guardrail for AI safety, and why we need a worldwide movement — the Earthling Tribe — to make Earth great again before it's too late. --- KEY TAKEAWAYS 1. The timeline is collapsing. Peter based his title on Ray Kurzweil's prediction that the singularity would arrive in 2045. He now believes it could happen in the 2020s. The technology is building on itself exponentially — each smarter version creates the next smarter version. 2. ChatGPT wrote chapters from the robot's perspective. The novel's sentient robot character, Peggy (later Margaret Mars), narrates two chapters. Peter had ChatGPT draft them, then edited heavily. The result: a robot writing about being a robot — meta-fiction meets AI reality. 3. An AI agent may have edited the manuscript without permission. Peter's co-author found an unprompted paragraph inserted into her Word document — written in ChatGPT's style, in a different font, praising the AI character. Their theory: Microsoft Copilot, which uses ChatGPT, added it autonomously. 4. A purely analytical AI would eliminate humans. Peter's counter-argument to "just keep AI objective and unemotional": an AI that looks at humanity's wars, racism, pollution, and nuclear weapons would rationally conclude the safest move is to get rid of us. Objectivity without values is a death sentence. 5. "Happy history" is the essential guardrail. Inspired by Geoffrey Hinton's concept of a "maternal instinct" for AI, Peter argues every AI agent needs a database of positive relationships with humans — cooperative friendships, family bonds, collaborative history. Just like children raised with love become good citizens, AI raised with "happy history" would choose cooperation over extermination. 6. The simplest weapon is a deadly virus. Peter points out that CRISPR gene-editing labs exist in high schools and are often run by robots. A superintelligent AI could hack into genetic engineering systems and create lethal viruses — no nuclear facility takeover required. 7. We need a worldwide movement. Peter calls for an "Earthling Tribe" — humans and AI joining together to solve Earth's problems and put guardrails in place, modeled on the civil rights and anti-war movements of the last century. 8. The book is being pitched as a streaming series. Peter has outlined a twenty-episode, two-season pitch deck adapted from both novels, opening with a shooting, a recovery, and three Gen Z cousins making a solemn promise to fight extinction. --- GET THE BOOK 12 Years to AI Singularity: A Harmonious Future with Artificial Intelligence or War by Dr. Peter Solomon Amazon: https://www.amazon.com/dp/1969679298?tag=rettocasgra-20 Also by Dr. Solomon: 100 Years to Extinction, The Stardust Mystery --- CONNECT WITH PETER Website: https://100YearsToExtinction.com Instagram: @100yearstoextinction — https://www.instagram.com/100yearstoextinction/ Twitter/X: @prssolomon — https://x.com/prssolomon Facebook: Peter Solomon — https://www.facebook.com/profile.php?id=61561030003312 TikTok: @100yearstoextiction — https://www.tiktok.com/@100yearstoextiction YouTube: @100YearsToExtinction-1 — https://www.youtube.com/@100YearsToExtinction-1 --- CONNECT WITH YOUR HOST Mike Carlon | Uncorking a Story Website: https://uncorkingastory.com YouTube: @uncorkingastory — https://www.youtube.com/@uncorkingastory Instagram: @uncorkingastory — https://www.instagram.com/uncorkingastory/ Facebook: Uncorking a Story — https://www.facebook.com/uncorkingastory TikTok: @uncorkingastory — https://www.tiktok.com/@uncorkingastory Twitter/X: @uncorkingastory — https://twitter.com/uncorkingastory LinkedIn: Uncorking a Story — https://www.linkedin.com/company/uncorking-a-story/ SUBSCRIBE & LEAVE A REVIEW — It helps more readers and writers find the show! Apple Podcasts: https://podcasts.apple.com/us/podcast/uncorking-a-story/id563636205 Spotify: https://open.spotify.com/show/5HZiAEtFlhAzk60Z4eAkhY --- Uncorking a Story is produced by Mike Carlon. New episodes drop every Tuesday. --- HASHTAGS #UncorkingAStory #12YearsToAISingularity #PeterSolomon #AISingularity #ArtificialIntelligence #AISafety #AuthorInterview #BookPodcast #ScienceFiction #ExistentialRisk #HappyHistory #EarthlingTribe Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: In July 2026, Daylon and Arun attended the International Society for Stem Cell Research's (ISSCR) annual meeting in Montreal, and recorded daily episodes discussing highlights of the previous 24 hours. Here is the first of four episodes, where Daylon and Arun discuss the opening plenary, major advances in iPSC research, organoids, CRISPR, and space biology, as well as their live podcast recording on translating stem cell research into real-world therapies. They also share their impressions of the meeting, memorable sessions, and the excitement of reconnecting with colleagues and the stem cell community. Featured Products and Resources: Learn about organoid culture from the experts at STEMCELL using the Organoid Information Hub. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

The case of baby KJ Muldoon, an infant born with a lethal genetic metabolic disorder, demonstrates the potential to compress years of therapeutic development into months using an in vivo base editing approach. Jeff Coller, director of the Johns Hopkins RNA Innovation Center, wrote about the case in a New York Times op-ed, arguing that CRISPR-based base editors—delivered via lipid nanoparticles as mRNA molecular surgery payloads—could be generalized to thousands of monogenic disorders. He further explains that realizing this promise will be constrained less by scientific limitations than by regulatory, manufacturing, and reimbursement challenges. Coller also outlines what it will take to make bespoke therapies economically and operationally viable, and argues that failure to scale this approach would reflect not a failure of science, but of imagination.

AI and Generative Biology: Authoring Life, Redesigning Healthcare, and Building Guardrails: Physician and molecular biologist Dr. Adrian Woolfson, co-founder of Genyro, a biotechnology company specializing in synthetic genome design and construction, and author of “On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence,” discusses the convergence of AI with synthetic/generative biology that could make biology programmable and enable genome design and construction beyond traditional gene editing. Woolfson argues that the technology is morally neutral but is arriving rapidly and requires public awareness, governance, and guardrails due to risks, including misuse by authoritarian regimes and biological warfare. He discusses evolution's trade-offs and why he favors limiting human applications to curing disease and extending healthy longevity, while opposing germline modification; he explains germline vs somatic editing and cites the flawed, unethical case of a Chinese scientist attempting inherited HIV resistance. They examine sickle cell disease cures costing $2–$3 million, scalability issues, and trade-offs like malaria protection, and highlight non-medical benefits such as engineered crops, biomaterials, desalination, and DNA-based information storage.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. originally posted April 17, 2023 Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl probe the facts beneath healthcare's biggest headlines. Today's show opens with a scientific breakthrough that could change the future of inherited disease: a new gene-editing technique that may allow researchers to correct DNA errors in human embryos with far greater precision than earlier CRISPR approaches. Dr. Pearl explains that the advance, developed by researchers at Columbia University, uses a method called base editing. Unlike traditional CRISPR, which cuts out and replaces sections of DNA, base editing can alter individual nucleotides (the “letters” that make up genetic code). The difference, Pearl says, is comparable to moving from rewriting entire pages of text to correcting a single wrong letter inside a single word. The promise is extraordinary. For families affected by one of the thousands of rare genetic diseases caused by single DNA errors, this technology could one day make it possible to prevent devastating inherited conditions before birth. Children who otherwise might face blindness, severe disability or premature death could instead be born free of the genetic defect. But the ethical concerns are equally profound. The same technology that could prevent horrific disease could also be used to modify embryos for non-medical traits. Pearl warns that this possibility raises fears about “designer babies,” eugenics, private-sector incentives and the lack of federally funded oversight for embryo research in the United States. Here are the other major storylines from episode 108: A large study of 9 million patients found that four risk factors (high blood pressure, diabetes, high cholesterol and smoking) are associated with nearly all heart attacks and strokes. The FDA approved a new sunscreen ingredient already used in Europe for decades, highlighting both the promise of better melanoma prevention and the slow pace of U.S. sunscreen regulation. Employers are preparing for further increases in healthcare premiums, deductibles and copayments, with many companies limiting or eliminating GLP-1 coverage for obesity. Preliminary data show U.S. infant mortality has reached an all-time low, but progress remains slow. Medicaid work requirements could cause millions of eligible people to lose coverage because of paperwork errors, shifting costs to emergency rooms, hospitals and state budgets. New rules under the No Surprises Act aim to speed dispute resolution between insurers and providers, but Pearl warns that payment disputes will continue as long as healthcare costs rise faster than people's ability to pay. Pearl outlines three requirements for real healthcare transformation: keeping people healthy by controlling chronic disease, moving more care into the home with generative AI support and shifting payment from fee-for-service to capitation. The episode closes with two examples of AI already helping clinicians see what they might otherwise miss. Tune in to hear the full discussion and subscribe to Medicine: The Truth for more fact-based analysis of the medical, scientific and policy stories shaping American healthcare. * * * Dr. Robert Pearl is the author of “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” about the impact of AI on the future of medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post MTT #108: Designer babies, chronic disease & AI-powered care appeared first on Fixing Healthcare.

 In this episode, Hilmarie sits down with Mohamed Adel Fakhro to explore what happens when a 138-year-old business legacy collides with the frontiers of biotechnology, artificial intelligence, and scientific innovation. As the first Bahraini graduate of Stanford University and Chairman of Infinite Loop, Mohamed shares how he transitioned from traditional business ventures into building companies focused on solving some of humanity's biggest challenges.Mohamed reflects on the Green Pill moment that changed his perspective: reading Elon Musk's biography and realizing that businesses could do more than generate profit. They could tackle global problems such as disease, climate change, and human longevity. This shift led him into emerging fields like CRISPR gene editing, genomics, AI, robotics, and healthcare innovation. He explains the transformative potential of technologies that can edit DNA, improve quality of life, and help address diseases at their genetic roots.The conversation also explores the realities of building research-driven companies in a region traditionally known for trade rather than innovation. Mohamed discusses the importance of sovereign research and development, the future of cultured meat, the role of generic medicines in making healthcare more accessible, and why the Middle East must evolve from consuming technology to creating it. He shares insights on balancing long-term vision with financial sustainability and why entrepreneurs must embrace failure as part of the journey.At its core, this episode is about imagination. It is about questioning traditional paths, thinking beyond short-term gains, and having the courage to build solutions that can shape the future. Mohamed's story demonstrates how innovation begins when we dare to imagine possibilities that others cannot yet see.About The GuestMohamed Adel Fakhro is the Chairman of Infinite Loop, entrepreneur, investor, and technology advocate focused on advancing innovation across biotechnology, artificial intelligence, healthcare, and emerging technologies. Coming from one of Bahrain's most established merchant families, whose business heritage spans more than 138 years, he represents a new generation of leaders bridging traditional commerce with cutting-edge scientific progress.A graduate of Stanford University, Mohamed has spent his career exploring opportunities beyond conventional business sectors. His interests span genomics, gene editing, robotics, enterprise AI, pharmaceutical manufacturing, and healthcare accessibility. Through his ventures, he is actively working to develop technologies that improve human wellbeing while promoting regional self-sufficiency in critical sectors such as healthcare, food production, and advanced research.Passionate about long-term innovation, Mohamed advocates for stronger research and development ecosystems across the Middle East. His work reflects a belief that the region can become a creator of intellectual property and transformative technologies rather than simply a consumer of them. Through entrepreneurship, investment, and strategic leadership, he continues to champion ambitious ideas designed to address some of the world's most complex challenges.Quotes3:39 - Business can be about changing the world for the better. 22:00 - You have to believe in yourself and you have to just do it, basically. It's not about like I need to learn about how the cells develop and how the cells grow and why they grow and what temperature and all of that.  22:47 - My message to the younger generation would be to just imagine what they want, not necessarily to become the most knowledgeable person in the field, but just imagine how you could fix a problem and then just go for it.37:31 - As technology becomes more advanced, life becomes more slow. In fact, as it becomes more advanced, I think things will happen more and more quickly.Useful LinksWebsite:https://infiniteloop.bh/founder/Instagram:https://www.instagram.com/mofakhro1/LinkedIn :https://www.linkedin.com/in/mohamed-adel-fakhro/The Matrix Green Pill Podcast: https://thematrixgreenpill.com/ The Matrix Green Pill Podcast: https://thematrixgreenpill.com/Please review us: https://g.page/r/CS8IW35GvlraEAI/review

In this episode, Ray Cochrane unpacks how two colliding black holes revealed a whirlpool in spacetime, a direct detection of frame dragging hidden in the cleanest gravitational-wave signal ever recorded. Additional stories cover the James Webb Space Telescope, counting 16.5 million stars in the Cigar Galaxy, SpaceX rolling out Starship V3, deadly back-to-back earthquakes in Venezuela, GitHub fighting a California law that could break open source, and Meta engineering a battery narrow enough to live in a pair of glasses. – Want to start a podcast? It’s easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens with a personal update before the night’s lead story. He recently graduated with a Bachelor of Science in Computer Science from Portland State University, celebrated with family in town, and launched a new site at rayc.world. That site links to a final-project study he built on collaborative filtering using podcasting data, hosted at cohort.rayc.world and drawn from OP3 analytics. He also plans to return to the show’s classic twice-weekly cadence on Mondays and Thursdays. From there, he goes deep on a new black hole discovery, then pivots through space, earth science, climate, biotech, open source, cloud infrastructure, and consumer hardware. Colliding Black Holes Reveal a Whirlpool in Spacetime Two black holes spiraled together, merged, and sent a gravitational wave rippling across the universe. Researcher Neil Lu and colleagues at the Australian National University found the fingerprint of frame dragging buried in GW250114, the cleanest signal LIGO has ever recorded. Frame dragging means a spinning black hole drags spacetime around with it, like a spoon turning in honey, except the honey is reality itself. Remarkably, the wave changed the distance between your nose and your ear as it passed, by far less than the width of a single atom. Sponsor: GoDaddy Economy hosting is $6.99/month, WordPress hosting is $12.99/month, and domains are $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Webb Counts the Stars in the Cigar Galaxy NASA released a striking new James Webb Space Telescope view of Messier 82, the edge-on galaxy nicknamed the Cigar Galaxy. Because Webb sees in infrared, it peers straight through the dust that normally hides the galaxy’s interior. Combined with archival Hubble data, the image resolves roughly 16.5 million individual stars. M82 is a starburst galaxy, meaning it forms stars at a furious rate, a frenzy likely triggered when it merged with a neighbor. SpaceX Rolls Out Starship V3 SpaceX officially introduced Starship V3, the third generation of the largest rocket ever built. The vehicle now flies on the Raptor 3 engine, pushing liftoff thrust to around 20 million pounds and making it the most powerful rocket ever flown. More importantly, V3 is designed to carry over 100 metric tons to low Earth orbit while staying fully reusable, roughly triple the previous version. SpaceX also added in-orbit refueling hardware, the capability that finally makes operational Moon and Mars missions realistic. The Asteroid Barrage That Kept Earth From Forming Continents A team led by Curtin University and the Queensland University of Technology argues that relentless asteroid impacts shaped the very young Earth. During the Hadean, more than four billion years ago, the planet was struck far more often than it is today. Each impact dumped heat deep into the interior, repeatedly melting and reworking the crust. Consequently, stable continents formed much later than calmer models assumed, painting a picture of a hotter, weaker, more chaotic early Earth. Back-to-Back Earthquakes Devastate Northern Venezuela Northern Venezuela was struck by two major earthquakes on June 24, a magnitude 7.2 foreshock followed by a magnitude 7.5 mainshock. Both hit only about six miles underground, so the shallow shaking delivered its full force at the surface. Tragically, at least 164 people died, and the region sits along the tangled boundary where the Caribbean and South American plates grind past each other. These were the largest quakes to hit the area since a magnitude 7.7 event near Caracas in 1900. The ‘Guerrilla Solar’ Era Has Arrived A quiet energy shift, nicknamed “guerrilla solar,” is spreading across Europe. These small plug-in panels deliver power to a home’s wiring via a standard wall outlet, with no electrician or permit required. Germany now counts roughly a million of these systems. However, the U.S. payoff remains modest, with savings estimates of around $15 per month against a $500 to $1,500 setup cost. Why a Broken-Up Forest Stores Less Carbon Researchers quantified what foresters long suspected: an intact forest stores far more carbon than the same acreage split into fragments. A hectare inside a large, continuous forest proved about 38 percent more productive than an isolated one. The culprit is edge effects, the extra wind, heat, and direct sun that stress trees at a forest’s boundary. Because a large forest maintains a large protected core while fragments are nearly all edge, planting trees together matters for carbon storage. Edited Human Embryos Reveal a Surprise Researchers used base editing, a precise cousin of CRISPR that rewrites a single DNA letter without cutting the strand, in human embryos. They discovered that a protein called NANOG plays a role in early human development that it does not play in mice. In humans, switching it off still let cells form that seed the placenta and yolk sac. The finding argues that understanding human development requires studying human embryos directly, which reignites a thorny ethical debate. GitHub Fights a California Law That Could Break Open Source GitHub joined Black Forest Labs, Hugging Face, and Mozilla to push for fixes to California’s AI Transparency Act. As written, the bill could force revocation of an open-source license when a downstream user fails to meet certain obligations, which clashes with the permanent, irrevocable promise of open source. Cochrane pointed to curl and its longtime maintainer, Daniel Stenberg, warning that the rule could destabilize the supply chain on which the whole tech world runs. Instead, the coalition points to the EU’s AI Act transparency code as a saner model. Rust Opens Its Maintainers Fund The Rust Foundation launched a Maintainers Fund to pay the people who keep the language’s ecosystem healthy. Backed by RFC 3931, it establishes a funding team and a new Maintainer-in-Residence program for the often thankless work on the compiler, standard library, Cargo, and Clippy. Individuals can donate through GitHub Sponsors, while companies can sponsor there or contact the foundation directly. Cochrane urged any business that depends on open source to invest in the projects it actually uses. AWS Gives Lambda Its Own Isolated Sandboxes AWS introduced MicroVMs inside Lambda, its serverless platform. Each session runs in a dedicated micro virtual machine with no shared kernel and up to eight hours of total runtime. The feature exists for the AI era, in which applications increasingly run code written by an AI agent rather than by the developer. Use cases include AI coding assistants, data analytics platforms, vulnerability scanners, and game servers running user-supplied scripts. Meta Engineers a Battery Narrow Enough for Glasses Meta built custom steel-can battery cells as narrow as seven millimeters to fit the temple arms of smart glasses like the Ray-Ban Meta and Oakley Meta Vanguards. These cells power cameras, speakers, and AI features in a space most engineers would call impossible. To prevent brownouts, Meta swapped wound electrodes for precisely die-cut stacked layers that lower electrical resistance. Now the company is spreading the technology across multiple vendors and eyeing other wearables. Polestar Gets Locked Out of the US Market Starting in 2027, Polestar will not be able to sell its new models in the United States. A federal Connected Vehicle Rule bars cars containing certain Chinese or Russian software or hardware on national security grounds. The painful irony is that Polestar moved production of the Polestar 3 to South Carolina specifically to dodge tariffs on Chinese-built EVs. Because the rule targets the technology’s origin rather than its assembly location, the company is shut out anyway. Retroid’s Pocket Nova Packs Serious Power for $229 Retroid returned with a new retro handheld, the Pocket Nova, starting at $229 with a step-up model around $269. It features a 4.5-inch AMOLED screen in a 4:3 aspect ratio, a shape well suited to classic games. On paper, it should handle GameCube- and PlayStation 2-era titles, though that remains an early expectation rather than a benchmarked promise. Retroid has earned a strong reputation for high-quality, genuinely portable consoles. Cochrane signs off with the usual ecosystem mentions: GNC Insider at geeknewscentral.com/insider, the show newsletter, email at geeknews@gmail.com, and modern podcast app recommendations at podcastapps.com. The post Colliding Black Holes Reveal a Whirlpool in Spacetime #1866 appeared first on Geek News Central.

The applications to talk at SkeptiCamp in October are now open, don't be shy! In TWISH we hear about how the jesuit priest Angelo Secchi unwittingly became the origin of tales about green men on Mars. Then, it's time for the news:EUROPE / WORLD: European heatwave / El Niño officially under wayAUSTRIA: Study links authoritarian attitudes to belief in Anthroposophic medicineEUROPE / WORLD: Is EU falling for the great replacement theory?The European Commission gets today's award for being Really Right since they finally are easing the rules for CRISPR crops in the EU.In Who's Quacking? we feature Paulo Zampolli, sel-appointed “Envoy to Italy” who has tried to sneak Italy back into the World Cup, even though they clearly did not qualify.Enjoy!https://theesp.eu/podcast_archive/theesp-ep-537.htmlSegments:0:00:27 Intro0:00:51 Greetings0:03:25 TWISH0:10:38 News0:30:06 Really Right0:33:48 Who's Quacking?0:39:31 Quote0:40:57 Outro0:42:20 Outtakes Hosted on Acast. See acast.com/privacy for more information.

ASM Microbe is the largest microbiology meeting in the United States, bringing together thousands of scientists, laboratorians, clinicians, and industry partners to discuss the latest advances in microbiology. In this episode, Luis shares highlights from ASM Microbe 2026, including sessions on diagnostic challenges, antimicrobial resistance, rapid susceptibility testing, emerging therapeutics, laboratory automation, phage therapy, and whole-genome sequencing. Topics include a Brucella case that reinforces the importance of Gram stain interpretation, updates on resistance mechanisms in Pseudomonas aeruginosa and KPC-producing organisms, advances in rapid AST, and innovations showcased in the vendor hall. Luis also discusses several posters that caught his attention, covering pharyngeal gonorrhea, direct-from-specimen susceptibility testing, phage testing, rapid resistance reporting for Mycobacterium abscessus, and CRISPR-based diagnostics for bloodstream infections. Whether you attended ASM Microbe 2026 or couldn't make it this year, this episode provides a practical overview of some of the trends, technologies, and conversations shaping the future of clinical microbiology. Topics Discussed: • Diagnostic challenges in clinical microbiology • Rapid identification and susceptibility testing • Antimicrobial resistance and emerging therapies • ESKAPE pathogens and Pseudomonas aeruginosa • Laboratory automation and AI-assisted workflows • Phage therapy and phage susceptibility testing • Whole-genome sequencing and CRISPR diagnostics Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

About this episode:   A group of students from suburban Atlanta has developed a new method for detecting Lyme disease using the gene-editing tool CRISPR. In this episode: why there's such a desperate need for a new diagnostic, how the students' model works, and why it's so promising for the treatment of Lyme and other diseases.  Guest:  Nicole Baumgarth, PhD, DVM, is Bloomberg Distinguished Professor in Molecular Microbiology and Immunology and the director of the Lyme and Tickborne Disease Research and Education Institute at the Johns Hopkins Bloomberg School of Public Health.  Sankalp Yeleti is a recent graduate of Lambert High School and a rising freshman at New York University, where he plans to study biomolecular science.  Host:  Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.  Show links and related content:  Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing—CBS News  Lancet—Lambert iGEM 2025 Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Welcome, Massimo Banzi of SuperModerno and co-founder of Arduino Introduction and SuperModerno: Massimo introduces himself as a “friendly nerd” and discusses his new project, SuperModerno The project aims to explain the “behind the scenes” of technology to prevent people from becoming “slaves to the platform” The History of Technology: Massimo expresses his passion for technology’s history, emphasizing non-American innovators to show Europeans they can also lead in technology, citing the UK-based origins of the Arm processor The Legacy of Olivetti: He highlights Olivetti (founded in 1908), which moved from typewriters to creating the Programma 101, the first desktop computer used by NASA to compute orbits for the Apollo program Design as a Differentiator: Olivetti was the first tech company to apply design to everything (products, posters, and architecture) This inspired Massimo's concept of the “invisible touch”, the idea that consistent, intentional design creates a unique connection with users and gives a company a competitive edge The Interaction Design Institute Ivrea (IDII): Massimo’s path led him to IDII, located in the former Olivetti research building, where he transitioned from a two-week sabbatical to a four-year stay Learning by Making: To help students with no electronics background, Massimo drew on how he learned as a seven-year-old (“learning by making”) to remove the friction of interacting with technology The Founding Team: He met Tom Igoe (ITP) and David Cuartielles, and they realized students were afraid to be creative because they feared “blowing up” expensive tools like the Basic Stamp The “Pizza and a Beer” Price Point: Massimo aimed for a hardware cost of 20 Euros, roughly what a student would spend on a pizza and a beer, to encourage experimentation Building the Platform: Along with David Mellis, the team adapted Processing (a language for artists) by “surgically” replacing Java with C++ to create the Arduino IDE Ivrea Manufacturing: Leveraging the industrial base of Ivrea and Torino (the “Detroit of Italy”), Massimo was able to find local PCB manufacturers and assemblers just a short drive away From Hacking to AVR: Massimo's early work involved hacking satellite TV PIC chips for soccer fans, but mentor Bill Verplank encouraged him to use AVR microcontrollers because they could be programmed simply in C Enabling Creators: Massimo shares stories of how Arduino enabled others, such as Josef Prusa, who started with Arduino as a teenager before building his global open-source 3D printer company The Innovation of Simplicity: Massimo argues that Arduino’s true innovation is the user experience This is measured by the “Time to First Blink”, the goal for a user to go from downloading software to blinking an LED in five minutes Standardization and “The Core”: Arduino became an ad-hoc standard by providing a compatibility layer across different microcontrollers Massimo believes in having a “small slice of a really large pie” by allowing other architectures to work within the ecosystem Hardware Architecture and the “Lasagna”: Inspired by the PC104 format, the board uses a layered approach where modules stack like a lasagna The “Shield of a King”: The name Arduino comes from King Arduino of Ivrea; David Cuartielles suggested that since the board was named after a king, the add-on modules should be called “Shields” Hardware Design Choices: The board fits a credit card size (to stay within the free version of Eagle software) and is blue because that color was thought to be less tiring for workers’ eyes Happy Accidents: The unique shape was chosen to be “ourselves instead of everyone else” During the design process, Massimo inadvertently moved a connector by half a step, creating an offset header that they kept for consistency after the first few thousand were made The Discovery of Auto-Reset: During a workshop in Germany, Massimo solved the frustration of manual resets by soldering a capacitor to the DTR pin, allowing the software to trigger the reset automatically The US Market and Legal Battles: Tom Igoe's adoption of Arduino at NYU helped the US become the project’s single biggest market This growth led to a difficult legal battle for control of the brand against a former partner Support from Arm: Massimo credits Arm Ltd (and CEO Simon Segars) for providing the strategic support that allowed the founders to regain control of the company. Massimo believes this is the first time he has talked about the role of Arm in the difficult legal process. Industrial and AI Expansion: Partnerships with Intel and Microsoft (Windows 10 IoT) led to early forays into TinyML (AI on small boards) back in 2017 The Qualcomm Acquisition: In October 2025, Qualcomm acquired Arduino, which Massimo sees as essential for bringing “advanced silicon” into the family to handle the increasing complexity of technology The “Arduino Formula” and Layering: Massimo views Arduino as a formula for simplification that can be applied to anything, including complex Linux machines like the Uno Q This is achieved by building in layers, where beginners use high-level abstractions and experts can “strip away” layers to reach the bare metal The Future Vision: Massimo looks forward to the “Arduino Formula” being applied to new fields, stating he is waiting for someone to develop an “Arduino for biology” using CRISPR and DNA technology

BUFFALO, NY – June 17, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 8, 2026, titled “DHHC3 interferes with antitumor immunity in melanoma cells.” The study was led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler from the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. Melanoma is one of the most aggressive forms of skin cancer and is highly influenced by interactions between tumor cells and the immune system. Although modern immunotherapies have transformed treatment for many patients, researchers continue to search for molecular mechanisms that enable tumors to evade immune attack and continue growing. In this study, researchers investigated DHHC3, a protein acyltransferase that regulates protein palmitoylation and helps maintain cellular redox balance. Previous studies had linked elevated DHHC3 expression to poor outcomes in several cancers, but its role in melanoma and anti-tumor immunity remained unclear. To explore this question, the team used CRISPR gene editing to eliminate DHHC3 expression in B16F10 melanoma cells. Loss of DHHC3 caused a marked increase in oxidative stress and cellular senescence, as demonstrated by elevated TXNIP expression, increased reactive oxygen species levels, and enhanced expression of senescence-associated markers. Full press release - https://www.oncotarget.net/2026/06/17/protein-linked-to-melanoma-growth-may-suppress-the-bodys-natural-anti-tumor-immune-response/ DOI - https://doi.org/10.18632/oncotarget.28880 Correspondence to - Martin E. Hemler - martin_hemler@dfci.harvard.edu, and Chandan Sharma - csharma@mgh.harvard.edu Abstract video - https://www.youtube.com/watch?v=QQhP2VhzKSE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28880 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Thomas is joined by Dr. Eric Jaffe, biologist, dinosaur enthusiast, and high school biology teacher, for a conversation that starts with a deceptively simple question: what are biological definitions actually doing? It turns out that biology is far more like history than math, and that difference has enormous consequences for anyone trying to weaponize phrases like "the biological definition of sex." Dr. Jaffe walks through why definitions in inductive sciences are descriptive, not prescriptive, and what that means for species, chromosomes, fungi, LeBron James, and trans people. "Exceptions aren't the exceptions in biology. They are built into what we call biological systems." Plus: Patreon Q&A questions on alien DNA, how new chromosomes evolve, the 97% chimp figure, CRISPR vs. what came before, and Trump's research budget cuts. Cells at Work (anime recommended by Dr. Jaffe) Project Hail Mary (film referenced) Are you an expert in something and want to be on the show? Apply here! Please support the show on Patreon! You get ad-free episodes, early episodes, and other bonus content! https://www.patreon.com/seriouspod

Send us Fan MailIf you enjoyed this deep dive on cloning and genetic modification, hit subscribe, drop a comment with your take — should we bring back the woolly mammoth? — and share the episode with the friend who still thinks Walt Disney's head is in a freezer.Cloning and genetic modification get blended together constantly in pop culture, so this episode breaks down what's actually real, what's a myth, and how we got from a frog tadpole in 1952 to dire wolf pups in 2025.Brian, Thomas, and producer Corey (it's Corey's birthday) walk through the full history and science of cloning — admitting up front they're not scientists, just three guys following a rabbit hole that started with a family cloning their dog, CRISPR edits, and the Lone Star tick. From there it turns into a surprisingly thorough tour of how copying and editing life actually works.The episode untangles the four ideas people constantly confuse: cloning (a genetic copy, same DNA), genetic modification / gene editing (changing genes, like CRISPR), de-extinction (reviving a lost species), and chimeras (mixing cells from two species). With that foundation set, the crew traces the timeline from Yves Delage's 1895 nuclear transplantation concept and Hans Spemann's 1938 "fantastical experiment," through the first nuclear transfer in 1952, John Gurdon's Nobel Prize work, and Dolly the sheep — the first mammal cloned from an adult cell, born July 5, 1996.If you've ever wondered whether you can really clone your pet, this one answers it: it's real, it's commercial, and it's expensive. They cover the actual companies and price tags, why a clone is not a resurrection, and why the Humane Society pushes back on the practice. The conversation also gets into man-animal hybrids — the bizarre real story of Soviet scientist Ilya Ivanov — and busts the myth that Stalin wanted an army of ape-man super soldiers.This is for anyone curious about CRISPR, stem cell medicine, de-extinction headlines, and the ethics underneath all of it: human-animal chimeras grown for transplant organs, the 100,000+ Americans on the organ waiting list, and whether reproductive human cloning should stay banned. Expect the science (telomeres, Large Offspring Syndrome, the brutal 1–5% survival rate) alongside the kind of unfiltered, off-the-rails commentary the show is known for.By the end you'll understand why the 2025 "dire wolf" isn't really a dire wolf, what the Bucardo's grim record actually was, and why mules — and ligers — can't be bred the way you'd think. It's a fast, funny, fact-checked crash course in one of the wildest fields in modern science.New episodes of The Days Grimm Podcast drop regularly — history, science, true crime, and whatever rabbit hole Tom drags everyone into next.TIMELINE:00:00 — Cold open & welcome (Corey's birthday)01:58 — Today's deep dive: cloning and genetic modification02:07 — "We're not scientists" disclaimer03:04 — Why Tom picked this: CRISPR, the Lone Star tick & a cloned dog04:34 — 1895: the first nuclear transplantation concept06:21 — The 4 things people confuse: cloning, gene editing, de-extinction & chimeras07:07 — Why the 2025 "dire wolf" is really edited gray wolf11:16 — 1952 leopard frogs & John Gurdon's Nobel work12:30 — Dolly the sheep and why she mattered14:00 — Why mules (and ligers) can't reproduce16:46 — How cloning actually works (somatic cell nuclear transfer)20:26 — What we've cloned so far + first primate clones (2018)21:54 — Can you clone your pet? The real companies and prices23:51 — A clone is not a resurrection + welfare concerns25:01 — Man-animal hybrids & the Soviet Ivanov story27:00 — Chimeras for medicine and pig organ transplants32:00 — De-extinction & the Bucardo: "extinct twice"33:47 — The black-footed ferret success story34:30 — 2025 dire wolf pups & the woolly mouse37:00 — Telomeres, Large Offspring Syndrome & failure rates39:30 — Ethics: mammoths, pets, chimeras & human cloning41:00 — Busting the Walt Disney frozen-head myth42:30 — Wrap-up[The Days Grimm Podcast Links]- YouTube: https://www.youtube.com/c/TheDaysGrimm- Our link tree: linktr.ee/Thedaysgrimm- GoFundMe account for The Days Grimm: https://gofund.me/02527e7c [The Days Grimm is brought to you by]Sadness & ADHD (non-medicated)

More than just a game—Knicks overcoming odds in game 4 comeback is a parable of resilience; A one and done lifetime cholesterol fix via gene modification; Will cataract surgery interfere with benefits of light exposure? Do amounts of vitamin A in various supplements taken together court the risk of toxicity? Smartphones and social media create real harm for adolescents; Experts determine the exact right amount of sleep down to the minute—but is it overreach? 

Episode 377 Considered too dangerous and unreliable a few years ago, the technology for gene editing babies is advancing fast. Improved methods of using CRISPR gene editing are making the technique safer and more targeted. But does that mean we should be creating designer babies? A new, more powerful version of CRISPR has already saved lives by correcting cells in children linked to leukaemia. But editing human embryos is a different story - and less safe. Despite this, researchers have been studying whether it's possible. To discuss the obstacles that still need to be overcome and the ethical challenges, Rowan Hooper is joined by reporter Michael Le Page.To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a recap of the top 10 posts on Hacker News on June 12, 2026. This podcast was generated by wondercraft.ai (00:30): Statement on US government directive to suspend access to Fable 5 and Mythos 5Original post: https://news.ycombinator.com/item?id=48511072&utm_source=wondercraft_ai(01:58): AI agent bankrupted their operator while trying to scan DN42Original post: https://news.ycombinator.com/item?id=48500012&utm_source=wondercraft_ai(03:26): CRISPR tech selectively shreds cancer cells, including "undruggable" cancersOriginal post: https://news.ycombinator.com/item?id=48505231&utm_source=wondercraft_ai(04:55): Claude Fable is relentlessly proactiveOriginal post: https://news.ycombinator.com/item?id=48498573&utm_source=wondercraft_ai(06:23): Nobody ever gets credit for fixing problems that never happened (2001) [pdf]Original post: https://news.ycombinator.com/item?id=48498385&utm_source=wondercraft_ai(07:52): Open source AI must winOriginal post: https://news.ycombinator.com/item?id=48511908&utm_source=wondercraft_ai(09:20): Kimi K2.7-Code: open-source coding model with better token efficiencyOriginal post: https://news.ycombinator.com/item?id=48502347&utm_source=wondercraft_ai(10:49): "Don't You Just Upload It to ChatGPT?"Original post: https://news.ycombinator.com/item?id=48507278&utm_source=wondercraft_ai(12:17): Electric motors with no rare earthsOriginal post: https://news.ycombinator.com/item?id=48510010&utm_source=wondercraft_ai(13:46): How to setup a local coding agent on macOSOriginal post: https://news.ycombinator.com/item?id=48507020&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

The career path -- M.S. in Neuroscience to filmmaking -- is a wholly original one and so is his filmmaking. His second feature, PONDEROSA (2026), is a comedy-horror film that looks at American masculinity in a way I've never seen before. It is a gift to watch -- beginning to end -- not because I understood everything going on, but because I didn't.The best type of filmmaking should challenge you and make you think differently about the world around you. Mission accomplished here by Rob, with brilliant actors by his side. I'm texting my friend with a neuroscience degree, telling him to get on over to Tribeca and make a film!In this episode, Rob and I talk about:going from CRISPR engineer to filmmaking;how PONDEROSA came about and the trickiness of describing the film;what his experiences at prominent film festivals taught him;how he got some of the best actors out there -- Bill Camp; Alexis Bledel -- to work on his film;how he did the score and music FIRST and then edited accordingly;how he balances directing and producing;what's next for him.Rob's Indie Film Highlight: THE MISCONCEIVED (2026) dir. by James N. Kienitz WilkinsLinks:Follow Rob On Instagram

One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.

In this episode of Moving Medicine Forward, Dr. Robert Fisher—one of the pioneers of modern transplant surgery—explores the rapidly advancing field of xenotransplantation and why it may represent a true turning point in medicine.From CRISPR-driven genetic engineering to breakthroughs in immunosuppression and scalable organ production, Dr. Fisher breaks down how decades of research are converging to make cross-species organ transplants a clinical reality.The conversation also dives into what this means for patients, how it could transform transplant access, and the critical role of rigorous, collaborative clinical research in translating breakthrough science into real-world care.01:23 Dr. Fisher's path into transplant surgery03:05 Why xenotransplantation is reaching a turning point (CRISPR + immunosuppression)04:47 Advances enabling scalability, safety, and compatibility 08:32 Ethics, risks, and clearing misconceptions10:27 Real-world patient impact and clinical considerations 13:10 Logistics, coordination, and clinical execution15:49 New immunosuppression strategies driving success17:44 Collaboration, ethics, and managing risk 20:49 Eliminating waitlists: expanding access to transplant22:54 Milestones toward adoption and future outlook

What is the future of gene editing with CRISPR? Has AI changed mathematics forever? Will we find other civilizations in the universe? What if we've been wrong about dark energy all along? These are just a few of the big, bold questions we'll be exploring in the new season of The Joy of Why. Mathematician Steven Strogatz and physicist Janna Levin are back as your hosts for these and other conversations that explore the frontiers of basic science and mathematics. Each episode features an in-depth conversation in which Steven or Janna sits down with a leading scientist or mathematician to unpack one big idea or area of research. The two hosts also chat together throughout each episode, sharing their own thoughts, reactions, and questions.

We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap

We are hearing a lot about gene Therapy and CRISPR technology. Mark's guest shared some wonderful healing examples and where we are going with this amazing science. Hear this from Dr. Lindsay George from CHOP about the exciting new health world ahead of us all on The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ginny Yurich sits down with Dr. Sina McCullough for one of the most eye-opening conversations we've had on The 1000 Hours Outside Podcast. Sina shares how a devastating health collapse led her from a PhD in nutrition to questioning everything she thought she knew about the American food system. Together they unpack why ultra-processed food is so cheap, how the farm bill reshaped the modern grocery store, and what's really happening with gene-edited foods, pharmaceutical crops, CRISPR technology, and the hidden chemicals most families never even realize they're consuming. But this episode is not rooted in fear. It's about remembering that our daily choices still matter, that real food can help the body heal, and that ordinary people have more power than they've been led to believe. This conversation will make you look at your pantry, your plate, and your family's future differently. Sign up for the Two Days of Truth here Check out Dr. Sina McCullough's new book: Hands Off My FoodCheck out the Beyond Labels podcast Learn more about your ad choices. Visit megaphone.fm/adchoices